We’re currently experiencing extremely high call volumes. We’re very sorry for any inconvenience this might cause.

If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Biogen Inc (BIIB) USD (CDI)

Sell:$295.00 Buy:$335.00 Change: $8.19 (2.69%)
NASDAQ:3.79%
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Sell:$295.00
Buy:$335.00
Change: $8.19 (2.69%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Sell:$295.00
Buy:$335.00
Change: $8.19 (2.69%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Contact details

Address:
225 Binney St
CAMBRIDGE
02142-1031
United States
Telephone:
+1 (781) 4642000
Website:
https://www.biogen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BIIB
ISIN:
US09062X1037
Market cap:
$53.08 billion
Shares in issue:
174.06 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Stelios Papadopoulos
    Independent Chairman of the Board
  • Michel Vounatsos
    Chief Executive Officer, Director
  • Jeffrey Capello
    Chief Financial Officer, Executive Vice President
  • Ginger Gregory
    Chief Human Resource Officer, Executive Vice President
  • Susan Alexander
    Executive Vice President, Chief Legal Officer and Secretary
  • Alphonse Galdes
    Executive Vice President, Pharmaceutical Operations and Technology
  • Chirfi Guindo
    Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
  • Daniel Karp
    Executive Vice President, Corporate Development
  • Alfred Sandrock
    Executive Vice President, Research and Development, Chief Medical Officer
  • Robin Kramer
    Chief Accounting Officer, Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.